Selective Cyclized α‑Melanocyte-Stimulating Hormone Derivative with Multiple N‑Methylations for Melanoma Imaging with Positron Emission Tomography
journal contributionposted on 07.05.2020, 20:46 by Chengcheng Zhang, Zhengxing Zhang, Jutta Zeisler, Nadine Colpo, Kuo-Shyan Lin, François Bénard
In this study, we designed and evaluated a novel α-melanocyte-stimulating hormone derivative with four N-methylations for melanocortin 1 receptor-targeted melanoma imaging with positron emission tomography (PET). The resulting peptide, DOTA-Pip-Nle4-Cyclo[Asp5-N-Me-His6-d-Phe7-N-Me-Arg8-N-Me-Trp9-N-Me-Lys10]αMSH4‑10-NH2 (CCZ01099), showed high receptor selectivity, greatly improved stability, and rapid internalization. [68Ga]Ga-CCZ01099 showed clear tumor visualization and excellent tumor-to-normal tissue contrast with PET imaging in a preclinical melanoma model. Therefore, CCZ01099 is a promising compound for imaging and potentially radioligand therapy for melanoma.
Read the peer-reviewed publication
receptor selectivityMelanoma ImagingMe-Trp 9radioligand therapyPET imagingpositron emission tomographyDOTA-Pip-Nle 4NH 2tumor-to-normal tissue contrasttumor visualizationnovel α- melanocyte-stimulating hormoneCCZ 01099Positron Emission Tomographyd-Phe 7MSHmelanocortin 1 receptor-targeted melanoma imagingMe-Arg 8melanoma modelMe-His 6